Brief: NRX Pharmaceuticals Announces Enrollment Completion Of Its Phase 2B/3 Trial Of Nrx-101 In Suicidal Treatment Resistant Bipolar Depression
22/01/2024 12:20
Jan 22 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS, INC. (NASDAQ: NRXP) ANNOUNCES
COMPLETION OF
ENROLLMENT OF ITS PHASE 2B/3 TRIAL OF NRX-101 IN SUICIDAL
TREATMENT RESISTANT BIPOLAR DEPRESSION
* NRX PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED
LATER
THIS QUARTER
* NRX PHARMACEUTICALS INC: STUDY EXCEEDED ORIGINALLY TARGET
ENROLLMENT
Source text for Eikon: ID:nPn7TmB9Ha
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview